Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Coleman Lindsley, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Robert Lindsley and Benjamin Ebert.
Connection Strength

3.960
  1. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547.
    View in: PubMed
    Score: 0.734
  2. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View in: PubMed
    Score: 0.634
  3. The biology and clinical impact of genetic lesions in myeloid malignancies. Blood. 2013 Nov 28; 122(23):3741-8.
    View in: PubMed
    Score: 0.577
  4. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013 Jan 24; 8:21-47.
    View in: PubMed
    Score: 0.539
  5. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604.
    View in: PubMed
    Score: 0.218
  6. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
    View in: PubMed
    Score: 0.217
  7. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
    View in: PubMed
    Score: 0.182
  8. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016 Mar; 22(3):288-97.
    View in: PubMed
    Score: 0.171
  9. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 02; 126(1):9-16.
    View in: PubMed
    Score: 0.162
  10. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25; 371(26):2488-98.
    View in: PubMed
    Score: 0.158
  11. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
    View in: PubMed
    Score: 0.154
  12. Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood. 2021 Mar 25; 137(12):1628-1640.
    View in: PubMed
    Score: 0.061
  13. Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background. Blood. 2019 06 13; 133(24):2610-2614.
    View in: PubMed
    Score: 0.053
  14. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019 04; 51(4):694-704.
    View in: PubMed
    Score: 0.053
  15. Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest. 2016 10 03; 126(10):3827-3836.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.